Abstract
Inflammation participates in the initiation and progression of atherosclerotic cardiovascular disease, and it is a critical inciting factor leading to acute ischemic events. Evidence has shown that certain anti-inflammatory medications used to treat non-atherosclerotic inflammatory diseases reduce cardiovascular events. This article reviews evidence that commonly used anti-inflammatory therapies (colchicine, allopurinol, methotrexate), reduce cardiovascular events. We discuss potential mechanisms of action, efficacy, and safety of these therapies and propose a clinical trials design to investigate their efficacy.
| Original language | English |
|---|---|
| Pages (from-to) | 223-232 |
| Number of pages | 10 |
| Journal | Cardiovascular Drugs and Therapy |
| Volume | 32 |
| Issue number | 2 |
| DOIs | |
| State | Published - 1 Apr 2018 |
Keywords
- Allopurinol
- Atherosclerosis
- Cardiovascular disease
- Colchicine
- Inflammation
- Methotrexate